Biohaven Insiders Bought $33.9 Million of Stock Before the SK Biopharm Deal
A director and Biohaven's own CEO bought $33.9 million of BHVN on the open market at $7.50 a share, months before its $400 million SK Biopharmaceuticals deal. Here is the real read.
Biohaven’s CEO and its biggest director bought the stock at $7.50, then the deal hit
On August 26, 2026, Biohaven ($BHVN) signed a global licensing deal with SK Biopharmaceuticals worth $400 million upfront, and the insiders who look smartest today are the ones who bought the stock months earlier at $7.50 a share. NexusAlert flagged the licensing 8-K the same day the deal crossed the wires, tagged it High severity under Merger/Acquisition, and paired it with the detail a headline skips: Biohaven was the rare company where insiders had been buying, not selling, into the news.
Net insider flow at Biohaven is +$33.9M of buying. Most companies in this week’s headlines were net sellers. Biohaven was not.
What the filing actually says
Biohaven’s Irish subsidiary granted SK Biopharmaceuticals an exclusive, worldwide license to its Kv7 ion channel platform, led by opakalim (BHV-7000), an investigational treatment for focal epilepsy. The terms: a $400 million upfront fee, with $350 million due at closing on August 26 and another $50 million in 2027, plus up to $150 million in development and regulatory milestones and tiered royalties on net sales. Wire coverage framed the full package at up to roughly $795 million.
The key word is upfront. This is a cash infusion for a clinical-stage biotech, not a dilutive stock sale, and it validates a platform Biohaven has spent years building.
The misconception worth busting
Open your feed on any given day and the insider headlines are almost all sales. Here is the part most readers miss: the large majority of that selling is noise. Shares withheld at vesting to cover taxes, automatic 10b5-1 plans set months in advance, strategic holders trimming for their own reasons. None of it tells you much about conviction.
Open-market buying is the opposite. When executives and directors reach into their own pockets and buy shares at the market price, there is really only one reason to do it. Insiders sell for a hundred reasons. They buy for one.
The bigger pattern the Dossier surfaces
This is where the filing and the insider record line up. The NexusAlert Company Dossier shows Biohaven with net insider flow of +$33.9M across 18 transactions, and every notable line is a buy. Director John W. Childs bought $25.0 million of stock. Director Gregory Bailey added $3.0 million. CEO Vlad Coric bought $5.0 million through two family trusts. All of it in November 2025, all at $7.50 a share, well below where the stock trades today. There is no Form 144 on file, so no planned selling sits behind the buying.
Timing matters here, and it cuts against the cynical read. These buys landed months before the SK deal, when Biohaven was working through a rough stretch, not front-running an announcement. That is conviction into weakness, which is the hardest kind to fake.
The Dossier puts a number on it. Biohaven’s Insider Conviction score is 6.7 out of 10, in the top 33% of companies NexusAlert scores. The honest counterweight sits right next to it: Earnings Quality is 0.2, in the bottom 2%, because this is a cash-burning clinical-stage company with no profits to show, which is exactly why a $400 million upfront check matters so much. Institutional Flow is a middling 4.9. This is conviction, not a unanimous vote.
The lesson
A press release tells you a deal got signed. A Form 4 tells you what the people running the company believed months earlier, with their own money. When a CEO and his board buy the stock at $7.50 and the market re-rates it on a $400 million deal, the buying was the signal and the pop was the confirmation.
Read the whole filing, not the headline. That is the entire reason NexusAlert exists: it reads every 8-K, Form 4, and Form 144 the moment it posts, separates real buying from tax-withholding noise, and puts the deal and the insider record on one page so you can see when they agree.
Create a free NexusAlert account and get the filings read for you the moment they hit EDGAR.
Sources
- Biohaven Ltd. Form 8-K, SEC EDGAR
- SK Biopharm strikes $800m deal for epilepsy drug from Biohaven, Korea Herald
- Biohaven trades cash for upside with $795M epilepsy drug deal, BioPharma Dive
- SK Biopharmaceuticals to In-License Epilepsy Drug Candidate Opakalim, BioSpace
- Biohaven jumps on $795M SK Biopharmaceuticals deal for epilepsy drug opakalim, Seeking Alpha
- Biohaven CEO Vlad Coric buys $5 million in company shares, Investing.com
- Biohaven Ltd. Executives Make Massive Stock Purchases, TipRanks
Prefer to own it outright? NexusAlert lifetime access is available for a one-time payment of $299 — no subscription, no recurring charges, all future Pro features included. Learn more →